(P-383) Reasons for discontinuation of CAB+RPV LA for HIV treatment in the OPERA Cohort: A CHORUS survey of healthcare providers

Monday, October 20, 2025

12:15 PM - 1:30 PM US ET

Location: Poster Hall B4-B5

Presenting Author(s)

Ricky K. Hsu, MD (he/him/his)

National Medical Director of Clinical Standards, Policy, & Education\ Associate Professor of Medicine
AIDS Healthcare Foundation/ NYU School of Medicine
New York, NY, United States

MO

Michael D. Osterman, PhD

Epividian, Inc.
Raleigh, North Carolina, United States
Jennifer S. Fusco, BS

Chief Science Officer
Epividian, Inc.
Durham, North Carolina, United States
RP

Rachel Palmieri Weber, PhD

Epividian, Inc.
Raleigh, North Carolina, United States
Michael G. Sension, MD (he/him/his)

Medical Director
can community health
Miami Beach, FL, United States
MW

Michael B Wohlfeiler, JD, MD

AIDS Healthcare Foundation
Miami, Florida, United States
QC

Quateka Cochran, MSNEd, RN, ACRN

AIDS Healthcare Foundation
Fort Lauderdale, Florida, United States
GS

Gayathri Sridhar, MBBS, MPH, PhD

Director
ViiV Healthcare
Fairfax, Virginia, United States
Vani Vannappagari, MBBS, MPH, PhD

Global Head, Epidemiology & Real World Evidence
ViiV Healthcare
Research Triangle Park, North Carolina, United States
KB

Kimberley Brown, PharmD

ViiV Healthcare
Durham, North Carolina, United States
Jv

Jean A. van Wyk, MBChB, MFPM

Medical Director
ViiV Healthcare, Brentford, UK
Brentford, England, United Kingdom
GF

Gregory P Fusco, MD, MPH

Epividian, Inc.
Raleigh, North Carolina, United States